ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record12 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05461235Anti-PD-1 Antibody CombinedWith Autologous DC and NKCells in the Treatment ofDigestive CarcinomaChina Medical University, ChinPhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedDRUGSPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerSintilimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundToripalimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundCamrelizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundTislelizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Pembrolizumab”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 2SintilimabClaude Opus 5.5BackgroundCurrent
Nov 2ToripalimabClaude Opus 5.5BackgroundCurrent
Nov 2CamrelizumabClaude Opus 5.5BackgroundCurrent
Nov 2TislelizumabClaude Opus 5.5BackgroundCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18SintilimabRule based · role ruleTestedOverridden
Nov 18ToripalimabRule based · role ruleTestedOverridden
Nov 18CamrelizumabRule based · role ruleTestedOverridden
Nov 18TislelizumabRule based · role ruleTestedOverridden

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.